News

The agreement includes an option for Merck to develop human monoclonal antibodies directed against antigens identified by Intercell to treat and protect against severe infections caused by group

AstraZeneca will receive $700 million for the sale, settled in cash. Following this transaction, Royalty Pharma will receive royalty revenue formerly payable to Cambridge Antibody Technology based on

Drugs granted priority status can be reviewed in six months, rather than the standard ten. Abbot said that the FDA based its decision on the results of a

The vaccine will be covered for individuals 60 years of age and older whose benefit plans provide coverage for vaccines. WellPoint already provides benefits for Zostavax based on

The Junovan new drug submission includes efficacy and safety data from a phase III trial of the bone cancer known as osteosarcoma. The trial was conducted by the

In Canada, a priority review is generally reserved for drugs intended to treat serious or life threatening conditions. Based on clinical trial data, Lucentis has the potential to

Ono has obtained exclusive rights to develop and commercialize RC-1291 in Japan, Korea and Taiwan under this agreement. Ono will pay Sapphire upfront and milestone payments as well

The new class of drugs that target the enzyme Aurora B could be an alternative to current treatments as they seem to be less toxic and are still

The phase II trial evaluates Cloretazine in two separate subpopulations of small cell lung cancer, sensitive relapsed disease and refractory disease. Sensitive relapsed disease is defined as relapse